AAV serotype 2 vectors preferentially integrate into active genes in mice
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Recombinant adeno-associated virus serotype 2 (rAAV2) is a promising vector for gene therapy because it can achieve long-term stable transgene expression in animals and human subjects after direct administration of vectors into various target tissues. In the liver, although stable transgene expression primarily results from extrachromosomal vector genomes, a series of experiments has shown that vector genomes integrate into host chromosomes in hepatocytes at a low frequency. Despite the low integration efficiency, recent reports of retroviral insertional mutagenesis in mice and two human subjects have raised concerns about the potential for rAAV2-mediated insertional mutagenesis. Here we characterize rAAV2-targeted chromosomal integration sites isolated from selected or non-selected hepatocytes in vector-injected mouse livers. We document frequent chromosomal deletions of up to 2 kb at integration sites (14 of 14 integrations, 100%; most of the deletions were <0.3 kb) and preferred integration into genes (21 of 29 integrations, 72%). In addition, all of the targeted genes analyzed (20 of 20 targeted genes, 100%) were expressed in the liver. This is the first report to our knowledge on host chromosomal effects of rAAV2 integration in animals, and it provides insights into the nature of rAAV2 vector integration into chromosomes in quiescent somatic cells in animals and human subjects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Yet, follow-up studies indicated that 53-62% of rAAV integrations in the liver fused into actively-transcribed genes, and 3-8% into ribosomal DNA [247].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [247]
In the citing paper
“preclinical data suggest AAV integration events occur in a dose-dependent manner with a preference for integration at sites of active transcription, tissue-specific promoters are protective against oncogenesis.178, 179, 180”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [180]
In the citing paper
“This number is similar to multiple estimates of random integration of AAV8 from the literature.35”
From Adeno‐associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo†‡ (2010) · cites this paper as [35]
Citations
Cites
Initial sequencing and analysis of the human genome
International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216
The sequence of the human genome
Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A., et al. (2001) · Science · doi:10.1126/science.1058040 · Cited by 13,909
Initial sequencing and comparative analysis of the mouse genome
Mouse Genome Sequencing Consortium (2002) · Nature · doi:10.1038/nature01262 · Cited by 7,187
HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832
Large-scale analysis of the human and mouse transcriptomes
Su, A. I., Cooke, M. P., Ching, K. A., Hakak, Y., Walker, J. R., Wiltshire, T., Orth, A. P., Vega, R. G., Sapinoso, L. M., Moqrich, A., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012025199 · Cited by 1,466
Kay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., J Tai, S., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,022 · cited 1×
“jpg" NDATA ITEM> ]> Recombinant adeno-associated virus serotype 2 (rAAV2) is a promising vector for gene therapy because it can achieve long-term stable transgene expression in animals and human subjects after direct administration of vectors into various target tissue”
BackgroundSelf-citationOverturf, K., Al-Dhalimy, M., Tanguay, R., Brantly, M., Ou, C.-N., Finegold, M., & Grompe, M. (1996) · Nature Genetics · doi:10.1038/ng0396-266 · Cited by 549 · cited 1×
“Because there is a selective repopulation of stable genetically modified FAH-positive hepatocytes in HTI mouse liver”
BackgroundSelf-citationMurine leukemia induced by retroviral gene marking
Li, Z., Düllmann, J., Schiedlmeier, B., Schmidt, M., von Kalle, C., Meyer, J., Forster, M., Stocking, C., Wahlers, A., Frank, O., et al. (2002) · Science · doi:10.1126/science.1068893 · Cited by 525 · cited 1×
“Despite the low integration efficiency, recent reports of retroviral insertional mutagenesis in mic”
BackgroundNakai, H., Yant, S. R., Storm, T. A., Fuess, S., Meuse, L., & Kay, M. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.6969-6976.2001 · Cited by 478 · cited 1×
“In the liver, although stable transgene expression primarily results from extrachromosomal vector genome”
BackgroundSelf-citationSOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data
Diehn, M. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg014 · Cited by 428 · cited 1×
“We assessed the transcriptional activity of each targeted gene using web-based public databases and browsers: NCBI UniGene, SOURC”
Method
Cited by
Items 101–200 of 400
Genetic engineering meets hematopoietic stem cell biology for next-generation gene therapy
Ferrari, S., Valeri, E., Conti, A., Scala, S., Aprile, A., Di Micco, R., Kajaste-Rudnitski, A., Montini, E., Ferrari, G., Aiuti, A., et al. (2023) · Cell Stem Cell · doi:10.1016/j.stem.2023.04.014 · Cited by 70
Self-citationEhrhardt, A., Xu, H., Dillow, A. M., Bellinger, D. A., Nichols, T. C., & Kay, M. A. (2003) · Blood · doi:10.1182/blood-2003-01-0314 · Cited by 77
Self-citationEhrhardt, A., Xu, H., Huang, Z., Engler, J. A., & Kay, M. A. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.01.010 · Cited by 73
Self-citationIn Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies
Patel, A. R., Bah, M. A., & Weiner, D. B. (2020) · BioDrugs · doi:10.1007/s40259-020-00412-3 · Cited by 78
Adeno-associated Vector Toxicity—To Be or Not to Be?
Büning, H., & Schmidt, M. (2015) · Molecular Therapy · doi:10.1038/mt.2015.182 · Cited by 71
The Role of DNA-PKcs and Artemis in Opening Viral DNA Hairpin Termini in Various Tissues in Mice
Inagaki, K., Ma, C., Storm, T. A., Kay, M. A., & Nakai, H. (2007) · Journal of Virology · doi:10.1128/jvi.01225-07 · Cited by 67
“Activation of this pathway would be detrimental, because it may promote unwanted concatemerization, which reduces transcriptional ability or induces gene silencing (32, 38); various vector genome rearrangements, which often disrupt the transgene expression cassette in the vector; and vector genome integration, which m…”
BackgroundSelf-citationThe next step in gene delivery: Molecular engineering of adeno-associated virus serotypes
Wang, J., Faust, S. M., & Rabinowitz, J. E. (2010) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.10.017 · Cited by 75
“integration into open chromatin has been observed [12,13].”
Effect of chromatin upon Agrobacterium T-DNA integration and transgene expression
Gelvin, S. B., & Kim, S. (2007) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/j.bbaexp.2007.04.005 · Cited by 78
Adeno-Associated Virus Site-Specific Integration and AAVS1 Disruption
Hamilton, H., Gomos, J., Berns, K. I., & Falck-Pedersen, E. (2004) · Journal of Virology · doi:10.1128/jvi.78.15.7874-7882.2004 · Cited by 61
“Recently, random integration and subsequent activation of cellular genes have created safety concerns about retrovirus vectors (13), and recombinant AAV vectors have also been shown to disrupt cellular genes (16, 25).”
BackgroundViral Vectors in Cancer Immunotherapy: Which Vector for Which Strategy?
Collins, S., Guinn, B., Harrison, P. T., Scallan, M. F., O’Sullivan, G. C., & Tangney, M. (2008) · Current Gene Therapy · doi:10.2174/156652308784049345 · Cited by 73
“However, when integration does occur, it has been demonstrated to be within active regions of the genome [120].”
BackgroundLópez-Gordo, E., Chamberlain, K., Riyad, J. M., Kohlbrenner, E., & Weber, T. (2024) · Viruses · doi:10.3390/v16030442 · Cited by 70
“In rare cases, the AAV genome can also integrate into the host DNA at a very low frequency [87,89].”
BackgroundAAV vector-mediated in vivo reprogramming into pluripotency
Senís, E., Mosteiro, L., Wilkening, S., Wiedtke, E., Nowrouzi, A., Afzal, S., Fronza, R., Landerer, H., Abad, M., Niopek, D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05059-x · Cited by 64
Adenoviral vectors for in vivo delivery of CRISPR-Cas gene editors
Rice-Boucher, P. J., Cui, X., & Curiel, D. T. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.09.003 · Cited by 71
The Role of Recombinant AAV in Precise Genome Editing
Bijlani, S., Pang, K. M., Sivanandam, V., Singh, A., & Chatterjee, S. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.799722 · Cited by 68
“to spontaneous breaks resulting in deletions, insertions, and translocations (Nakai et al., 2003; Miller et al., 2005; Nakai et al., 2005; Inagaki et al., 2007; Nguyen et al., 2021).”
BackgroundGene therapy for the fetus: is there a future?
David, A. L., & Peebles, D. (2007) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2007.08.008 · Cited by 66
Retargeting transposon insertions by the adeno-associated virus Rep protein
Ammar, I., Gogol‐Döring, A., Miskey, C., Chen, W., Cathomen, T., Izsvák, Z., & Ivics, Z. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks317 · Cited by 69
“Nevertheless, rAAV vectors can genomically integrate with a preference for integration into transcription start sites and CpG islands (20).”
BackgroundHackett, C. S., Geurts, A. M., & Hackett, P. B. (2007) · Genome biology · doi:10.1186/gb-2007-8-s1-s12 · Cited by 73
Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson’s disease
Dass, B., Olanow, C. W., & Kordower, J. H. (2006) · Neurology · doi:10.1212/wnl.66.10_suppl_4.s89 · Cited by 67
Homologous recombination is required for AAV-mediated gene targeting
Vasileva, A. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl455 · Cited by 61
“In cell culture, the rate of random integration was at 10%, and integration in vivo is known to occur predominantly in transcriptionally active genes (13,14).”
BackgroundProgress in the Use of Adeno-Associated Viral Vectors for Gene Therapy
Büning, H., Braun‐Falco, M., & Hallek, M. J. (2004) · Cells Tissues Organs · doi:10.1159/000079988 · Cited by 76
Gene therapy for Duchenne muscular dystrophy
Ramos, J. N., & Chamberlain, J. S. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1088780 · Cited by 69
“Additionally, AAV displays a very low frequency of integration into the host genome, reducing concerns related to insertional mutagenesis but precluding its utility for stable transduction of muscle stem cells [41-43].”
BackgroundGene therapy for Huntington's disease
Ramaswamy, S., & Kordower, J. H. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.030 · Cited by 57
“It has been shown that recombinant AAV vectors lose their ability to site-specifically integrate into cells and instead integrate randomly into active genes (Nakai et al., 2003).”
BackgroundOhbayashi, F., Balamotis, M. A., Kishimoto, A., Aizawa, E., Diaz, A., Hasty, P., Graham, F. L., Caskey, C. T., & Mitani, K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506598102 · Cited by 67
Pañeda, A., Lopez-Franco, E., Kaeppel, C., Unzu, C., Gil-Royo, A. G., D'Avola, D., Beattie, S. G., Olagüe, C., Ferrero, R., Sampedro, A., et al. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.166 · Cited by 60
“In contrast to other studies (Nakai et al. , 2003; Li et al. , 2011), rAAV5-cohPBGD revealed a largely random integration pattern in NHP hepatocytes after intravenous delivery.”
Designing Heart Performance by Gene Transfer
Davis, J., Westfall, M. V., Townsend, D., Blankinship, M., Herron, T. J., Guerrero-Serna, G., Wang, W., Devaney, E., & Metzger, J. M. (2008) · Physiological Reviews · doi:10.1152/physrev.00039.2007 · Cited by 59
Breton, C., Clark, P. M., Wang, L., Greig, J. A., & Wilson, J. M. (2020) · BMC Genomics · doi:10.1186/s12864-020-6655-4 · Cited by 57
Gene Therapy for Cystic Fibrosis
Mueller, C., & Flotte, T. R. (2008) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-008-8080-3 · Cited by 66
Recent developments in transposon-mediated gene therapy
Matteo, M. D., Belay, E., Chuah, M., & VandenDriessche, T. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.684875 · Cited by 63
“Consequently, the integration pattern of the SB transposon system seems safer compared to when integrating viral vectors are used [94,96-100].”
MethodProspects for gene therapy of haemophilia
Nathwani, A. C., Davidoff, A. M., & Tuddenham, E. G. D. (2004) · Haemophilia · doi:10.1111/j.1365-2516.2004.00926.x · Cited by 58
“Recent studies indicate that rAAV vectors also integrate into transcriptionally active genes of the host genome following liver-targeted delivery of vector particles in mice [ 39 ].”
BackgroundFuture of cell and gene therapies for Parkinson's disease
Isacson, O., & Kordower, J. H. (2009) · Annals of Neurology · doi:10.1002/ana.21473 · Cited by 61
“However, it has recently been shown in mice that AAV serotype 2 vectors preferentially integrate into active rather than quiescent genes.(149) In addition, this vector tends to transfer DNA to an episome outside of the host genome, which should preclude adverse events.”
BackgroundInagaki, K., Lewis, S. M., Wu, X., Ma, C., Munroe, D. J., Fuess, S., Storm, T. A., Kay, M. A., & Nakai, H. (2007) · Journal of Virology · doi:10.1128/jvi.00963-07 · Cited by 54
“Notably, preferential labeling of palindromes was not observed in our previous study (36, 40) (Fig.”
BackgroundResultInfluentialSelf-citationHackett, P. B., Aronovich, E. L., Hunter, D. W., Urness, M., Bell, J. B., Kass, S. J., Cooper, L. J. N., & McIvor, S. R. (2011) · Current Gene Therapy · doi:10.2174/156652311797415827 · Cited by 53
Kao, C.-Y., Yang, S.-J., Tao, M.-H., Jeng, Y.-M., Yu, I.-S., & Lin, S.-W. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-02-0154 · Cited by 50
“Unlike previous reports (5, 46, 47), only small hepatocellular adenomas were observed in our experiments.”
BackgroundResultEmerging vectors and targeting methods for nonviral gene therapy
Lavigne, M. D., & Górecki, D. C. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.3.541 · Cited by 51
“Unfortunately, many viral properties that make them potent vectors are also responsible for serious side effects: insertion into host genome can prolong expression of a therapeutic gene [3,10], but also cause insertional mutagenesis (which might be the case even with adeno-associated virus vectors) [13-15].”
BackgroundState-of-the-art 2003 on PKU gene therapy
Ding, Z., Harding, C. O., & Thöny, B. (2003) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.09.010 · Cited by 60
“, quiescent cells, preferentially into actively transcribed genes, and cause small genomic deletions, hence having the potential for dangerous side effects [39,40].”
BackgroundBoden, D., Pusch, O., Lee, F., Tucker, L. D., & Ramratnam, B. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2003.11.025 · Cited by 50
“rangements o f t he A AVS1 t arget [25, 26 ] with”
BackgroundHemophilia B and gene therapy: a new chapter with etranacogene dezaparvovec
Anguela, X. M., & High, K. A. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023010511 · Cited by 53
Liver-Targeted Gene Therapy by SV40-Based Vectors Using the Hydrodynamic Injection Method
Arad, U., Zeira, E., El-Latif, M. A., Mukherjee, S., Mitchell, L., Pappo, O., Galun, E., & Oppenheim, A. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.361 · Cited by 49
Approaches to improving the kinetics of adenovirus-delivered genes and gene products
Xu, Z., Mizuguchi, H., Sakurai, F., Koizumi, N., Hosono, T., Kawabata, K., Watanabe, Y., Yamaguchi, T., & Hayakawa, T. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.12.010 · Cited by 52
Gene therapy for optic nerve disease
Martin, K. R. G., & Quigley, H. A. (2004) · Eye · doi:10.1038/sj.eye.6701579 · Cited by 55
“Of particular concern is the theoretical risk of insertional oncogenesis, as the recombinant form of the virus mediates random incorporation of transgenes into the host chromosomes”
BackgroundIn Utero gene therapy: current challenges and perspectives
Waddington, S. N., Kramer, M. G., Hernández-Alcoceba, R., Buckley, S. M. K., Themis, M., Coutelle, C., & Prìeto, J. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.01.015 · Cited by 57
Jenke, A., Scinteie, M. F., Stehle, I. M., & Lipps, H. J. (2004) · Molecular Biology Reports · doi:10.1023/b:mole.0000031363.35839.46 · Cited by 49
Site‐Specific Integration with ϕC31 Integrase for Prolonged Expression of Therapeutic Genes
Ginsburg, D. S., & Calos, M. P. (2005) · Advances in genetics · doi:10.1016/s0065-2660(05)54008-2 · Cited by 48
Deciphering conundrums of adeno-associated virus liver-directed gene therapy: focus on hemophilia
Pierce, G. F., Fong, S., Long, B. R., & Kaczmarek, R. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.12.005 · Cited by 50
Lentiviral Gene Transfer into the Dorsal Root Ganglion of Adult Rats
Yu, G., Fischer, G. J., Jia, G., Reiser, J., Park, F., & Hogan, Q. H. (2011) · Molecular Pain · doi:10.1186/1744-8069-7-63 · Cited by 48
“[55] showed that this vector system is also promiscuous in its integration pattern, which may lead to oncogenesis [56].”
BackgroundEhrhardt, A., Yant, S. R., Giering, J. C., Xu, H., Engler, J. A., & Kay, M. A. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300011 · Cited by 43
“mouse liver integrate into genomic DNA and most of the integration occurs in active genes.(4) In sharp contrast to viral-based gene delivery approaches,”
BackgroundSelf-citationWang, Z., Lisowski, L., Finegold, M. J., Nakai, H., Kay, M. A., & Grompe, M. (2012) · Molecular Therapy · doi:10.1038/mt.2012.157 · Cited by 44
Self-citationAggarwal, R., Lu, J., Kanji, S., Joseph, M., Das, M., Noble, G. J., McMichael, B. K., Agarwal, S., Hart, R. T., Sun, Z., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039365 · Cited by 48
“However, advantages of using the nanofiber-expanded cells are that we do not need to induce CXCR4 expression using any viral methods, which has potential to integrate to the host genome [40].”
BackgroundAwakening gene therapy with Sleeping Beauty transposons
Essner, J. J., McIvor, R. S., & Hackett, P. B. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.04.015 · Cited by 44
Targeted gene insertion for molecular medicine
Voigt, K., Izsvák, Z., & Ivics, Z. (2008) · Journal of Molecular Medicine · doi:10.1007/s00109-008-0381-8 · Cited by 45
“As a result, transgene expression from rAAV predominantly results from episomal vector DNA, though some integration of viral episomes can occur, dragging along the problems described above [18].”
BackgroundDevelopment challenges associated with rAAV-based gene therapies
Bolt, M. W., Brady, J. T., Whiteley, L. O., & Khan, K. N. M. (2021) · The Journal of Toxicological Sciences · doi:10.2131/jts.46.57 · Cited by 49
Mandel, R. J., Bürger, C., & Snyder, R. O. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.08.008 · Cited by 47
Thiophilic interaction chromatography for supercoiled plasmid DNA purification
Sandberg, L., Bjurling, Å., Busson, P., Vasi, J., & Lemmens, R. (2004) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2003.10.036 · Cited by 44
Adeno-Associated Virus-Based Gene Therapy for Lifelong Correction of Genetic Disease
Brommel, C. M., Cooney, A. L., & Sinn, P. L. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.138 · Cited by 45
“In total, AAV2 posed the greatest risk of insertional mutagenesis.(89) In a large study of 695 mice evaluating serotypes 1, 2, 5, 7, 8, and 9, only one liver tumor was observed resulting in an incidence of 0.”
BackgroundAAV vectors and tumorigenicity
Kay, M. A. (2007) · Nature Biotechnology · doi:10.1038/nbt1007-1111 · Cited by 50
Self-citationProgress toward cell‐directed therapy for phenylketonuria
Harding, C. (2008) · Clinical Genetics · doi:10.1111/j.1399-0004.2008.01027.x · Cited by 51
“However, integration when it does occur appears to happen in actively transcribed regions of the genome (49) and possible insertional mutagenesis is a concern.”
BackgroundLever, A. M. L., Strappe, P., & Zhao, J. (2004) · Journal of Biomedical Science · doi:10.1007/bf02256092 · Cited by 58
Fah Knockout Animals as Models for Therapeutic Liver Repopulation
Grompe, M. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-55780-9_20 · Cited by 45
Self-citationA Novel AAV-mediated Gene Delivery System Corrects CFTR Function in Pigs
Cooney, A. L., Thornell, I. M., Singh, B. K., Shah, V. S., Stoltz, D. A., McCray, P. B., Zabner, J., & Sinn, P. L. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0006oc · Cited by 42
“Without the transposase, the number of puromycin-resistant colonies ranged from 10 to 66, which is likely the result of low-level random integration of AAV genomes (42, 43).”
BackgroundNew insights into stability of recombinant adenovirus vector genomes in mammalian cells
Rauschhuber, C., Noske, N., & Ehrhardt, A. (2011) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2011.01.006 · Cited by 45
AAV vectors transduce hepatocytes in vivo as efficiently in cirrhotic as in healthy rat livers
Sobrevals, L., Enguita‐Germán, M., Rodríguez‐Ortigosa, C. M., González‐Rojas, J., Alzaguren, P., Razquin, N., Prìeto, J., & Fortes, P. (2011) · Gene Therapy · doi:10.1038/gt.2011.119 · Cited by 43
Liang, C., Zhong, C., Sun, R., Liu, B., Huang, C., Qin, J., Zhou, S. Y., Shan, J., Liu, Y., & Ye, S. (2007) · Journal of Virology · doi:10.1128/jvi.00208-07 · Cited by 41
“Although studies have addressed the efficacy of AAV-mediated gene therapy in different human and mammalian cell types, the most efficient vector transduction in vivo has been reported in skeletal muscle and brain, followed by hepatocytes (4, 22, 29, 52, 58).”
BackgroundGellhaus, K., Cornu, T. I., Heilbronn, R., & Cathomen, T. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.167 · Cited by 40
“…as extrachromosomal episomes (Nakai et al. , 2001) and hence are able to serve as a donor for gene targeting, a few vector genomes will integrate more or less randomly into the host genome (Fisher et al. , 1997; Nakai et al. , 1999, 2003, 2005; Miller et al. , 2004, 2005; Inagaki et al. , 2008).”
InfluentialAdvances in AAV-mediated gene transfer for the treatment of inherited disorders
Hildinger, M., & Auricchio, A. (2004) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201153 · Cited by 46
Uncertainty in an era of transformative therapy for haemophilia: Addressing the unknowns
Pierce, G. F. (2020) · Haemophilia · doi:10.1111/hae.14023 · Cited by 39
Ahmed, O. A. A., Pourzand, C., & Blagbrough, I. S. (2006) · Pharmaceutical Research · doi:10.1007/s11095-005-8717-3 · Cited by 41
Gene therapy of liver diseases
Prìeto, J., Qian, C., Hernández-Alcoceba, R., González‐Aseguinolaza, G., Mazzolini, G. D., Sangro, B., & Kramer, M. G. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.7.1073 · Cited by 43
“To avoid the risk of insertional mutagenesis [30], elements enabling site-specific integration or recombination can be included in the vector [31-33].”
BackgroundMartins, K. M., Breton, C. A., Zheng, Q., Zhang, Z., Latshaw, C., Greig, J. A., & Wilson, J. M. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.134 · Cited by 38
AAV-Mediated Gene Delivery to the Liver: Overview of Current Technologies and Methods
Palaschak, B., Herzog, R. W., & Markusic, D. M. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9139-6_20 · Cited by 40
Adeno‐associated virus‐mediated gene transfer
Srivastava, A. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21819 · Cited by 40
“…that recombinant AAV vector genomes remain episomal, but those studies have been carried out in tissues that are post-mitotic [Duan et al., 1998; Nakai et al., 2003; Zhong rosine residues on the AAV2 capsid surface, Y252, Y272, Y444, Y500, Y700, s to phenylalanine residues…”
BackgroundCataldi, M. P., & McCarty, D. M. (2010) · Journal of Virology · doi:10.1128/jvi.00641-10 · Cited by 35
Ribosomal DNA Integrating rAAV-rDNA Vectors Allow for Stable Transgene Expression
Lisowski, L., Lau, A., Wang, Z., Zhang, Y., Zhang, F., Grompe, M., & Kay, M. A. (2012) · Molecular Therapy · doi:10.1038/mt.2012.164 · Cited by 36
Self-citationGene transfer to the outflow tract
Dang, Y., Loewen, R. T., Parikh, H., Roy, P., & Loewen, N. A. (2016) · Experimental Eye Research · doi:10.1016/j.exer.2016.04.023 · Cited by 36
“, 2005)), integrate without specificity, or insert into active genes (Nakai et al., 2003).”
BackgroundOrganoids and microphysiological systems: Promising models for accelerating AAV gene therapy studies
Ramamurthy, R. M., Atala, A., Porada, C. D., & Almeida-Porada, G. D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1011143 · Cited by 36
Han, Z., Zhong, L., Maina, N., Hu, Z., Li, X., Chouthai, N. S., Bischof, D., Weigel-Van Aken, K. A., Slayton, W. B., Yoder, M. C., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2007.161 · Cited by 35
“…preintegration site is still largely unknown, studies from other investigators have shown that AAV preferentially integrates into transcription start sites, active genes, sites near oncogenes, as well as DNA breakage sites (Miller et al ., 2002, 2004; Nakai et al ., 2003; Inagaki et al ., 2007).”
Gene therapy for neurodegenerative and ocular diseases using lentiviral vectors
Ralph, G. S., Binley, K., Wong, L., Azzouz, M., & Mazarakis, N. D. (2005) · Clinical Science · doi:10.1042/cs20050158 · Cited by 36
Challenges of Gene Therapy for the Treatment of Glycogen Storage Diseases Type I and Type III
Jauze, L., Monteillet, L., Mithieux, G., Rajas, F., & Ronzitti, G. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.102 · Cited by 34
“45,46 Starting from the identification of the molecular basis of GSDs, different approaches were tested to restore the expression of the mutated proteins and rescue the disease phenotype in animal models of hepatic GSDs. Vectors used to deliver a corrected copy of the transgene included adenovirus,…”
Gene therapy for hemophilia: an imperative to succeed
Hough, C. A., & Lillicrap, D. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01401.x · Cited by 38
Russell, D. W. (2003) · Nature Genetics · doi:10.1038/ng0703-241 · Cited by 34
Cell and Gene Therapy for Friedreich Ataxia: Progress to Date
Evans‐Galea, M. V., Pébay, A., Dottori, M., Corben, L. A., Ong, S. H., Lockhart, P. J., & Delatycki, M. B. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.180 · Cited by 41
“AAV (serotype 2) has also been demonstrated to preferentially integrate with low efficiency in active genes in mice (Nakai et al ., 2003).”
Liu, H., Liu, L., & Visner, G. A. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.01942.x · Cited by 33
“This observation is in sharp contrast to commonly used integrating viral vectors that preferentially integrate into active genes and promoter regions (21,22), and thus the use of these viral vectors for establishing transgeneexpressing cell lines may complicate the experimental results.”
ResultNeuroepithelial Tumor with AAV Integration after Intracisternal Magna Vector Delivery
Ahrens‐Nicklas, R. C., Kotch, C., Roche, A. M., Everett, J. K., Reddy, S., Santi, M., Madsen, P. J., Martos-Rus, C., Yrigollen, C. M., Small, J. C., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2601608 · Cited by 35
Jenke, A., Eisenberger, T., Baiker, A. E., Stehle, I. M., Wirth, S., & Lipps, H. J. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.533 · Cited by 32
“Even recombinant adenoviral associated vectors have been recently shown to integrate into the host genome where they can cause deletions of up to 2 kb at the integration sites (Nakai et al ., 2003).”
A role for adeno-associated viral vectors in gene therapy
Coura, R., & Nardi, N. B. (2008) · Genetics and Molecular Biology · doi:10.1590/s1415-47572008000100001 · Cited by 37
“Recently, the preferential integration of AAV2 vectors in transcriptionally active chromatin regions in hepatocytes has been demonstrated (Nakai et al., 2003; Russell, 2003).”
BackgroundChikhlikar, P. R., de Arruda, L. B., Agrawal, S., Byrne, B. J., Guggino, W. B., August, J. T., & Marques, E. T. A. (2004) · Virology · doi:10.1016/j.virol.2004.02.025 · Cited by 32
Podetz-Pedersen, K. M., Bell, J. B., Steele, T. W. J., Wilber, A. C., Shier, W. T., Belur, L. R., McIvor, R. S., & Hackett, P. B. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.128 · Cited by 31
“…where they may have increased chances of causing adverse effects as a result of activation of oncogenes or their regulators (Schroder et al. , 2002; Nakai et al. , 2003; Wu et al. , 2003; Laufs et al. , 2004; Mitchell et al. , 2004; Bushman et al. , 2005; De Palma et al. , 2005; Ciuffi et al. ,…”
Rawle, F., Chang, S., Brown, B. D., McKinven, A., Tinlin, S., Graham, F. L., Hough, C. A., & Lillicrap, D. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.624 · Cited by 31
Clinical and Translational Landscape of Viral Gene Therapies
Yudaeva, A., Kostyusheva, A. P., Kachanov, A., Brezgin, S. A., Ponomareva, N., Parodi, A., Pokrovsky, V. S., Lukashev, A. N., Chulanov, V., & Kostyushev, D. S. (2024) · Cells · doi:10.3390/cells13221916 · Cited by 31
Tao, M. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1145 · Cited by 31
Gene therapy for lysosomal storage disorders
Gritti, A. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.582036 · Cited by 33
“Although they are predominantly nonintegrating, with most of the transgene expression from stable episomes [39] it has been shown through direct sequencing that integration can occur [40].”
BackgroundCurrent status and prospects for gene therapy
Nathwani, A. C., Benjamin, R., Nienhuis, A. W., & Davidoff, A. M. (2004) · Vox Sanguinis · doi:10.1111/j.1423-0410.2004.00543.x · Cited by 30
Intégration des vecteurs AAV et mutagenèse insertionnelle
Rossi, A., & Salvetti, A. (2016) · médecine/sciences · doi:10.1051/medsci/20163202010 · Cited by 31
Maina, N., Han, Z., Li, X., Hu, Z., Li, Z., Bischof, D., Weigel-Kelley, K. A., Slayton, W. B., Yöder, M. C., & Srivastava, A. (2008) · Human Gene Therapy · doi:10.1089/hum.2007.143 · Cited by 31
“It is generally assumed that recombinant AAV vector genomes remain episomal, on the basis of studies that were carried out in postmitotic tissues (Duan et al ., 1998; Nakai et al ., 2003; Zhong et al ., 2006a; Inagaki et al ., 2007).”
Erythroid-Specific Expression of β-Globin by theSleeping BeautyTransposon for Sickle Cell Disease
Zhu, J., Kren, B. T., Park, C. W., Bilgim, R., Wong, P. Y.-P., & Steer, C. J. (2007) · Biochemistry · doi:10.1021/bi6024484 · Cited by 31
Santat, L. A., Paz, H., Wong, C., Li, L., Macer, J. A., Forman, S. J., Wong, K., & Chatterjee, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502902102 · Cited by 29
A primer to gene therapy: Progress, prospects, and problems
Zittersteijn, H. A., Gonçalves, M. A. F. V., & Hoeben, R. C. (2020) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12270 · Cited by 30
Vector Integration and Tumorigenesis
Kalle, C. V., Deichmann, A., & Schmidt, M. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.2525 · Cited by 31
“As expected, the majority of the vector-fusion sequences represented episomal concatemeric AAV rearrangements and showed large deletions of the vector-inverted terminal repeat sequences (Nakai et al., 2003; Inagaki et al., 2007; Li et al., 2011; Nowrouzi et al., 2012).”
Weltner, J., Anisimov, A., Alitalo, K. K., Otonkoski, T., & Trokovic, R. (2012) · Journal of Virology · doi:10.1128/jvi.06302-11 · Cited by 30
“Since reprogramming is accompanied by active cell proliferation, we hypothesized that integration of rAAV vectors into the host genome would not occur and that transgene-free iPSC clones could be generated (20, 31).”
BackgroundWang, H., Liu, Z., Li, C., Gil, S., Papayannopoulou, T., Doering, C. B., & Lieber, A. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000706 · Cited by 28
Hojo, M., Abe, T., Sugano, E., Yoshioka, Y., Saigo, Y., Tomita, H., Wakusawa, R., & Tamai, M. (2004) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.04-0059 · Cited by 30
“Although there is no known pathogenic effect of AAV in humans, the genome of AAV is incorporated into chromosomes at a region that is actively transcribing genes.(37,38) This may then induce small to large deletions of the chromosome.”
Background
Metadata
- Authors
- Nakai, H., Montini, E., Fuess, S., Storm, T. A., Grompe, M., & Kay, M. A.
- Affiliations
- Stanford Medicine (US)
- Oregon Health & Science University (US)
- Corresponding author
- Kay, Mark A
- Venue
- Nature Genetics
- Published
- 2003-06-01
- Volume
- 34
- Issue
- 3
- Pages
- 297-302
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2171427593
- Cited by
- 392
- References
- 29
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 13 · 2023: 12 · 2022: 11 · 2021: 11 · 2020: 18 · 2019: 8 · 2018: 10 · 2017: 10 · 2016: 8 · 2015: 13 · 2014: 8 · 2013: 7 · 2012: 19
- FWCI
- 22.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- AAV2, rAAV2, chromosomal integration, insertional mutagenesis, gene therapy vectors, hepatocytes, liver, somatic cells, transgene expression
- MeSH terms
- Dependovirus, Animals, Base Sequence, Cell Line, Chromosome Deletion, Chromosomes, Female, Genes, Genetic Vectors, Humans, Mice, Inbred C57BL, Molecular Sequence Data, Plasmids, Sequence Homology, Nucleic Acid, Transduction, Genetic, Genetic Therapy, Virus Integration, Gene Transfer Techniques, Transgenes, Hepatocytes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.